Product Pathways - Growth Factors/Cytokines
Human Epigen #5493
|5493LC||50 µg (With Carrier)||---||In Stock||---|
|5493LF||50 µg (Carrier Free)||---||In Stock||---|
|5493SC||10 µg (With Carrier)||---||In Stock||---|
|5493SF||10 µg (Carrier Free)||---||In Stock||---|
Recombinant human Epigen (hEpigen) Ala24-Ala104 (Accession #Q6UW88-1) was produced in E. coli at Cell Signaling Technology.
Recombinant hEpigen does not have a Met on the amino terminus and has a calculated MW of 9,087. DTT-reduced and non-reduced protein migrate as 8 kDa polypeptides with non-reduced protein having slightly greater mobility due to intramolecular cystines. The expected amino-terminal AVTVT of recombinant hEpigen was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hEpigen. All lots are greater than 98% pure.
The bioactivity of recombinant hEpigen was determined in a MCF-10A cell proliferation assay. The ED50 of each lot is between 2-30 ng/ml.
The purity of recombinant hEpigen was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hEpigen and staining overnight with Coomassie Blue.
The proliferation of MCF-10A cells treated with increasing concentrations of hEpigen was assessed. After 24 hr treatment, cells were labeled with BrdU for 4 hr. BrdU incorporation was determined by ELISA and the OD450-OD690 was determined.
Western blot analysis of extracts from MCF-10A cells untreated or treated with hEpigen for 10 minutes, using Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb #4370 (upper) and p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb #4695 (lower).
Less than 0.01 ng endotoxin/1 μg hEpigen.
With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hEpigen. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.
Epigen was identified as an EGF family member by amino acid sequence homology (1). The sequence was obtained from mouse keratinocyte mRNA. Epigen is expressed in normal human mammary tissue and in some prostate and breast carcinomas (2). Epigen binding to known EGF receptors is with lower affinity when compared to EGF. However, Epigen appears to be superior in inducing cell proliferation (2). Epigen induces responses in MDA-MB-468 breast carcinoma cells. Epigen also has effects on prostate cells and vascular endothelial cells (2). Epigen binds to ErbB1/Her1 (2). Binding causes receptor homodimerization and heterodimerization with other Erb/Her receptors (2).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.